Cargando…
A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315269/ http://dx.doi.org/10.1186/1479-5876-13-S1-O5 |
| _version_ | 1782355448710561792 |
|---|---|
| author | Dummer, Reinhard Daud, Adil Puzanov, Igor Hamid, Omid Schadendorf, Dirk Robert, Caroline Schachter, Jacob Pavlick, Anna Gonzalez, Rene Hodi, F Stephen Cranmer, Lee D Blank, Christian O’Day, Steven J Ascierto, Paolo A Salama, April K S Li, Nicole Xiaoyun Zhou, Wei Lis, Joy Ebbinghaus, Scot Kang, Peter S Ribas, Antoni |
| author_facet | Dummer, Reinhard Daud, Adil Puzanov, Igor Hamid, Omid Schadendorf, Dirk Robert, Caroline Schachter, Jacob Pavlick, Anna Gonzalez, Rene Hodi, F Stephen Cranmer, Lee D Blank, Christian O’Day, Steven J Ascierto, Paolo A Salama, April K S Li, Nicole Xiaoyun Zhou, Wei Lis, Joy Ebbinghaus, Scot Kang, Peter S Ribas, Antoni |
| author_sort | Dummer, Reinhard |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4315269 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-43152692015-02-12 A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma Dummer, Reinhard Daud, Adil Puzanov, Igor Hamid, Omid Schadendorf, Dirk Robert, Caroline Schachter, Jacob Pavlick, Anna Gonzalez, Rene Hodi, F Stephen Cranmer, Lee D Blank, Christian O’Day, Steven J Ascierto, Paolo A Salama, April K S Li, Nicole Xiaoyun Zhou, Wei Lis, Joy Ebbinghaus, Scot Kang, Peter S Ribas, Antoni J Transl Med Oral Presentation BioMed Central 2015-01-15 /pmc/articles/PMC4315269/ http://dx.doi.org/10.1186/1479-5876-13-S1-O5 Text en Copyright © 2015 Dummer et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Oral Presentation Dummer, Reinhard Daud, Adil Puzanov, Igor Hamid, Omid Schadendorf, Dirk Robert, Caroline Schachter, Jacob Pavlick, Anna Gonzalez, Rene Hodi, F Stephen Cranmer, Lee D Blank, Christian O’Day, Steven J Ascierto, Paolo A Salama, April K S Li, Nicole Xiaoyun Zhou, Wei Lis, Joy Ebbinghaus, Scot Kang, Peter S Ribas, Antoni A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma |
| title | A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma |
| title_full | A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma |
| title_fullStr | A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma |
| title_full_unstemmed | A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma |
| title_short | A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma |
| title_sort | randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4315269/ http://dx.doi.org/10.1186/1479-5876-13-S1-O5 |
| work_keys_str_mv | AT dummerreinhard arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT daudadil arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT puzanovigor arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT hamidomid arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT schadendorfdirk arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT robertcaroline arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT schachterjacob arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT pavlickanna arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT gonzalezrene arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT hodifstephen arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT cranmerleed arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT blankchristian arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT odaystevenj arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT asciertopaoloa arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT salamaaprilks arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT linicolexiaoyun arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT zhouwei arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT lisjoy arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT ebbinghausscot arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT kangpeters arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT ribasantoni arandomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT dummerreinhard randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT daudadil randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT puzanovigor randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT hamidomid randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT schadendorfdirk randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT robertcaroline randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT schachterjacob randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT pavlickanna randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT gonzalezrene randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT hodifstephen randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT cranmerleed randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT blankchristian randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT odaystevenj randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT asciertopaoloa randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT salamaaprilks randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT linicolexiaoyun randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT zhouwei randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT lisjoy randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT ebbinghausscot randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT kangpeters randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma AT ribasantoni randomizedcontrolledcomparisonofpembrolizumabandchemotherapyinpatientswithipilimumabrefractorymelanoma |